Aligos Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced that CEO Lawrence M. Blatt will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 5:15 pm ET. The presentation, conducted virtually, will include a Q&A session. An audio webcast of the presentation will be accessible through the Aligos investor section on their website. Aligos is focused on developing therapeutics for unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B and nonalcoholic steatohepatitis.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 5:15 pm ET. Both the presentation and the Q&A session will be held virtually.
An audio webcast of the presentation will be available through the Aligos investor section of the website. https://investor.aligos.com
The Aligos management team will also participate in investor 1x1 meetings during the conference. Please contact your J.P. Morgan Healthcare representative to schedule virtual one-on-one meetings with Aligos during the conference. For more information about the 40th Annual J.P. Morgan Healthcare Conference, please refer to the Conference Website.
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements.” Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2021, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
ajobe@lifescicomms.com
Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
FAQ
When will Aligos Therapeutics present at the J.P. Morgan Healthcare Conference?
Where can I listen to the Aligos presentation?
What is the focus of Aligos Therapeutics?
Who will be presenting for Aligos at the conference?
How can investors schedule meetings with Aligos during the conference?
